预测慢阻肺患者对贝那利珠单抗治疗反应的GALATHEA和TERRANOVA研究分析
GALATHEA和TERRANOVA试验中贝那利珠单抗未显著减少慢阻肺急性加重。本文分析3910例患者,发现血嗜酸性粒细胞升高合并频繁加重、肺功能差或支气管舒张反应强者可能从100mg每8周方案获益,30mg无效,结果需前瞻性验证。
核心结论
- 血嗜酸性粒细胞升高合并特定临床特征可识别从贝那利珠单抗100mg每8周治疗中减少急性加重的慢阻肺亚组。
- 30mg每8周方案在符合上述特征的患者中未显示优于安慰剂。
- 上述为假设生成性分析,需前瞻性临床试验验证。
研究设计与样本
- 对GALATHEA和TERRANOVA两项3期随机对照试验的个体研究和汇总结果进行事后分析。
- 共分析3910例接受贝那利珠单抗(30mg或100mg皮下每8周,前三次每4周)或安慰剂联合双联或三联吸入治疗的患者。
- 患者入组时年龄40-85岁,中度至极重度气流受限,血嗜酸性粒细胞升高,且前一年尽管接受双联或三联吸入治疗仍有至少2次加重或1次重度加重。
主要发现
- 在2665例血嗜酸性粒细胞升高的患者中,100mg每8周方案的治疗效应见于既往加重更频繁、基线肺功能更差或基线支气管舒张剂反应更大的患者,30mg方案未见。
临床怎么用
- 对血嗜酸性粒细胞≥220细胞/μL且前一年≥3次加重、肺功能差或支气管舒张反应大的慢阻肺患者,可考虑100mg每8周贝那利珠单抗以减少急性加重。
- 30mg每8周方案在上述亚组中未显示获益,不推荐使用。
- 该分析为假设生成性,临床决策需等待前瞻性试验验证。
局限性
- 为事后分析,存在多重比较和亚组分析固有偏倚。
- 结果需前瞻性临床试验验证方可指导临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benralizumab did not significantly reduce exacerbations compared with placebo in the phase 3 GALATHEA and TERRANOVA trials of benralizumab for patients with chronic obstructive pulmonary disease (COPD). We aimed to identify clinical and physiological characteristics of patients with COPD that could help to identify people who are likely to have the greatest treatment effect with benralizumab. METHODS: We analysed individual study and pooled results from GALATHEA and TERRANOVA. At study enrolment, patients from GALATHEA and TERRANOVA were aged 40-85 years, had moderate to very severe airflow limitation, had elevated blood eosinophil counts, and at least two exacerbations or one severe exacerbation in the previous year despite dual inhaled therapy (inhaled corticosteroids plus long-acting β2-agonists or long-acting β2-agonists plus long-acting muscarinic antagonists) or triple inhaled therapy (inhaled corticosteroids plus long-acting β2-agonists plus long-acting muscarinic antagonists). We analysed data for 3910 patients who received benralizumab (30 mg or 100 mg subcutaneously every 8 weeks; first three doses every 4 weeks) or placebo with dual or triple therapy to identify factors consistently associated with annual exacerbation rate reduction. We evaluated the annual exacerbation rate for benralizumab versus placebo as the primary endpoint. GALATHEA and TERRANOVA are registered with ClinicalTrials.gov, NCT02138916 and NCT02155660, respectively. FINDINGS: For 2665 patients with elevated blood eosinophil counts, treatment effect with benralizumab every 8 weeks at 100 mg, but not at 30 mg, occurred for patients with a history of more frequent exacerbations, poorer baseline lung function, or greater baseline lung function improvement with short-acting bronchodilators. Patients with baseline blood eosinophil counts of 220 cells per μL or greater with: three or more exacerbations in the previous year receiving benralizumab every 8 weeks versus placebo, had rate ratios (RRs) of 0·69 (95% CI 0·56-0·83) for 100 mg and 0·86 (0·71-1·04) for 30 mg; postbronchodilator FEV1 of less than 40% had RRs of 0·76 (0·64-0·91) for 100 mg and 0·90 (0·76-1·06) for 30 mg; and postbronchodilator response of at least 15% had RRs of 0·67 (0·54-0·83) for 100 mg and 0·87 (0·71-1·07) for 30 mg. When combined factors were examined, patients with elevated baseline blood eosinophil counts, with three or more exacerbations in the previous year, and who were receiving triple therapy were identified as likely to benefit from benralizumab 100 mg every 8 weeks versus placebo (RR 0·70 [95% CI 0·56-0·88]). Benralizumab 30 mg every 8 weeks did not benefit patients meeting these criteria compared with placebo (RR 0·99 [95% CI 0·79-1·23]). INTERPRETATION: Elevated blood eosinophil counts combined with clinical characteristics identified a subpopulation of patients with COPD who had reductions in exacerbations with benralizumab treatment. These hypothesis-generating analyses identified the potential efficacy of benralizumab 100 mg for this subpopulation. These findings require prospective evaluation in clinical trials. FUNDING: AstraZeneca.
引用
- Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2019. PMID: 31575508. doi:10.1016/S2213-2600(19)30338-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。